Bringing Together the CAR T-Cell Therapy Community

It’s easy to think of scientific researchers as existing in a vacuum: spending long days and evenings in a laboratory, making observations that most people will probably never understand or hear about. But when it comes to blood cancer research, that couldn’t be less true.

Every study is a chance to make a breakthrough—one that could change, and save, the lives of patients and their families. That’s why The Leukemia & Lymphoma Society (LLS) funds innovative research. We know we need as many minds as possible to close the gap to a new treatment—or a cure.

And LLS is far from alone in that goal. Gilead and Kite Oncology, one of LLS’s trusted and valued partners, makes groundbreaking cancer research their highest priority. And as part of our Light The Night events this year, LLS and Gilead and Kite Oncology are championing scientific breakthroughs like CAR-T cell therapy with “Innovation Celebrations."

“As the exclusive sponsor of the Innovation Celebrations, Gilead and Kite Oncology is honored to recognize patients who are living longer as a result of CAR T-cell therapy, and members of their support community. These celebrations serve as an opportunity for the CAR-T community to celebrate survivorship and align perfectly with our national presenting sponsorship of Celebration & Community for Light the Night,” said Chad Saward, Senior Director, Patient and Professional Relations, Kite, a Gilead Company.

These honorees’ lives have been changed, and saved, by research. More specifically, by a blood cancer treatment that’s come to the forefront of blood cancer research in the last three decades: CAR T-cell therapy.

Read the rest of the article at: https://lls.org/blog/bringing-together-car-t-cell-therapy-community